Long QT syndrome: From channels to cardiac arrhythmias

Journal of Clinical Investigation

Volumn 115, Issue 8, 2005, Pages 2018-2024

  Moss, Arthur J ^a,c   Kass, Robert S ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL; SODIUM CHANNEL;

HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; REVIEW;

ACTION POTENTIALS; ANIMALS; HUMANS; LONG QT SYNDROME; MYOCARDIAL CONTRACTION; POTASSIUM CHANNELS; SODIUM CHANNELS;

EID: 23644452804     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI25537     Document Type: Review

References (65)

1. Moss, A.J., et al. 1991. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 84:1136-1144.
2. Sanguinetti, M.C., and Zou, A. 1997. Molecular physiology of cardiac delayed rectifier K+ channels [review]. Heart Vessels. 12(Suppl.):170-172.
3. Bennett, P.B., Yazawa, K., Makita, N., and George, A.L. 1995. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 376:683-685.
4. Jervell, A., and Lange-Nielsen, F. 1957. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am. Heart J. 54:59-68.
5. Splawski, I., Timothy, K.W., Vincent, G.M., Atkinson, D.L., and Keating, M.T. 1997. Molecular basis of the long-QT syndrome associated with deafness. N. Engl. J. Med. 336:1562-1567.
6. Splawski, I., et al. 2000. Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 102:1178-1185.
7. Moss, A.J. 2003. Long QT syndrome. JAMA. 289:2041-2044.
8. Priori, S.G., Napolitano, C., Paganini, V., Cantu, F., and Schwartz, P.J. 1997. Molecular biology of the long QT syndrome: impact on management. Pacing Clin. Electrophysiol. 20:2052-2057.
9. Zareba, W., et al. 1998. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N. Engl. J. Med. 339:960-965.
10. Schwartz, P.J., et al. 2001. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 103:89-95.
11. Ackerman, M.J., et al. 2002. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin. Proc. 77:413-421.
12. Takenaka, K., et al. 2003. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation. 107:838-844.
13. Paavonen, K.J., et al. 2001. Response of the QT interval to mental and physical stress in types LQT1 and LQT2 of the long QT syndrome. Heart. 86:39-44.
14. Moss, A.J., et al. 2000. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 101:616-623.
15. Priori, S.G., et al. 2004. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 292:1341-1344.
16. George, A.L., et al. 1995. Assignment of the human heart tetrodotoxin-resistant voltage-gated Na+ channel alpha-subunit gene (SCN5A) to band 3P21. Cytogenet. Cell Genet. 68:67-70.
17. Wang, Q., et al. 1995. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 80:805-811.
18. Wang, Q., et al. 1995. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum. Mol. Genet. 4:1603-1607.
19. Abrief H., Wehrens, X.H., Benhorin, J., Kerem, B., and Kass, R.S. 2000. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation. 102:921-925.
20. Veldkamp, M.W., et al. 2000. Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel. Circ. Res. 86:E91-E97.
21. Schwartz, P.J., et al. 1995. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to NA+ channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 92:3381-3386.
22. Rosero, S.Z., Zareba, W., Robinson, J.L., and Moss, A. 1997. Gene-specific therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with mutation of the sodium channel gene. Ann. Noninvasive Electrocardiol. 2:274-278.
23. Windle, J.R., Geletka, R.C., Moss, A.J., Zareba, W., and Atkins, D.L. 2001. Normalization of ventricular repolarization with flecainide m long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann. Noninvasive Electrocardiol. 6:153-158.
24. Benhorin, J., et al. 2000. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 101:1698-1706.
25. Nagatomo, T., January, C.T., and Makielski, J.C. 2000. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. Mol. Pharmacol. 57:101-107.
26. January, C.T., Gong, Q., and Zhou, Z. 2000. Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2. J. Cardiovasc. Electrophysiol. 11:1413-1418.
27. Sanguinetti, M.C., Curran, M.E., Spector, P.S., and Keating, M.T. 1996. Spectrum of HERG K channel dysfunction in an inherited cardiac arrhythmia. Proc. Natl. Acad. Sci. U. S. A. 93:2208-2212.
28. Moss, A.J., et al. 2002. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation. 105:794-799.
29. Zareba, W., et al. 2003. Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. J. Cardiovasc. Electrophysiol. 14:1149-1153.
30. Shimizu, W., et al. 2004. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J. Am. Coll. Cardiol. 44:117-125.
31. Noble, D., and Tsien, R. 1968. The kinetics and rectifier properties of the slow potassium current in cardiac Purkinje fibres. J. Physiol. 195:185-214.
32. Noble, D., and Tsien, R.W. 1969. Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibres. J. Physiol. 200:205-231.
33. Sanguinetti, M.C., and Jurkiewicz, N.K. 1990. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96:195-215.
34. Kass, R.S., and Wiegers, S.E. 1982. The ionic basis of concent ration-related effects of noradrenaline on the action potential of calf cardiac purkinje fibres. J. Physiol. 322:541-558.
35. Sanguinetti, M.C., Jiang, C., Curran, M.E., and Keating, M.T. 1995. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 81:299-307.
36. Mitcheson, J.S., Chen, J., Lin, M., Culberson, C., and Sanguinetti, M.C. 2000. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 97:12329-12333.
37. Wang, Q., et al. 1996. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. 12:17-23.
38. Sanguinetti, M.C., et al. 1996. Coassembly of KvLQT1 and minK(ISK) proteins to form cardiac IKS potassium channel. Nature. 384:80-83.
39. Barhanin, J., et al. 1996. K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature. 384:78-80.
40. Splawski, I., Tristani-Firouzi, M., Lehmann, M.H., Sanguinetti, M.C., and Keating, M.T. 1997. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat. Genet. 17:338-340.
41. Marx, S.O., et al. 2002. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science. 295:496-499.
42. Kurokawa, J., Chen, L., and Kass, R.S. 2003. Requirement of subunit expression for cAMP-mediated regulation of a heart potassium channel. Proc. Natl. Acad. Sci. U. S. A. 100:2122-2127.
43. Kass, R.S., and Moss, A.J. 2003. Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J. Clin. Invest. 112:810-815. doi:10.1172/JCI200319844.
44. Furutani, M., et al. 1999. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation. 99:2290-2294.
45. Zhou, Z., Gong, Q., and January, C.T. 1999. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J. Biol. Chem. 274:31123-31126.
46. Picker, E., Obejero-Paz, C.A., Zhao, S., and Brown, A.M. 2002. The binding site for channel blockers chac rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J. Biol. Chem. 277:4989-4998.
47. Paulussen, A., et al. 2002. A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency. J. Biol. Chem. 277:48610-48616.
48. Rajamani, S., Anderson, C.L., Anson, B.D., and January, C.T. 2002. Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation. 105:2830-2835.
49. Gong, Q., Anderson, C.L., January, C.T., and Zhou, Z. 2004. Pharmacological rescue of trafficking defective HERG channels formed by coassembly of wild-type and long QT mutant N470D subunits. Am. J. Physiol. Heart Circ. Physiol. 287:H652-H658.
50. Stuhmer, W., et al. 1989. Structural parts involved in activation and inactivation of the sodium channel. Nature. 339:597-603.
51. Catterall, W.A. 1995. Structure and function of voltage-gated ion channels [review]. Annu. Rev. Biochem. 64:493-531.
52. Weidmann, S. 1952. The electrical constants of Purkinje fibres. J. Physiol. 118:348-360.
53. Motoike, H.K., et al. 2004. The Na+ channel inactivation gate is a molecular complex: a novel role of the COOH-terminal domain. J. Gen. Physiol. 123:155-165.
54. Kim, J., et al. 2004. Calmodulin mediates Ca2+ sensitivity of sodium channels. J. Biol. Chem. 279:45004-45012.
55. Donaldson, M.R., Yoon, G., Fu, Y.H., and Ptacek, L.J. 2004. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. Ann. Med. 36(Suppl. 1):92-97.
56. Andelfinger, G., et al. 2002. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am. J. Hum. Genet. 71:663-668.
57. Tristani-Firouzi, M., et al. 2002. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J. Clin. Invest. 110:381-388. doi:10.1172/JCI200215183.
58. Bendahhou, S., et al. 2003. Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. J. Biol. Chem. 278:51779-51785.
59. Splawski, I., et al. 2004. Ca(V) 1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 119:19-31.
60. Kass, R.S., and Sanguinetti, M.C. 1984. Calcium channel in activation in the cardiac Purkinje fiber. Evidence for voltage- and calcium-mediated mechanisms. J. Gen. Physiol. 84:705-726.
61. Schote, J.J., et al. 1995. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am. J. Hum. Genet. 57:1114-1122.
62. Chauhan, V.S., Tuvia, S., Buhusi, M., Bennett, V., and Grant, A.O. 2000. Abnormal cardiac Na(+) channel properties and QT heart rate adaptation in neonatal ankyrin(B) knockout mice. Circ. Res. 86:441-447.
63. Yong, S., Tian, X., and Wang, Q. 2003. LQT4 gene: the "missing" ankytin. Mol. Interv. 3:131-136.
64. Mohler, P.J., et al. 2003. Ankytin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 421:634-639.
65. Mohler, P.J., et al. 2004. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc. Natl. Acad. Sci. U. S. A. 101:9137-9142.